Company Overview and News
KUALA LUMPUR, Sept 24 — Bursa Malaysia snapped a three-session gains to end broadly lower pressured by selling in heavyweights stocks as most regional markets reacted negatively to renewed concerns over the US-China trade dispute, dealers said.
9385 PBLOF 1295 BSMAF HIPEF 7123 1818 5199
KUALA LUMPUR: Vertice Bhd, Daiman Development Bhd , Padini Holdings Bhd , Matrix Concepts Holdings Bhd and IOI Properties Group Bhd are among the stocks to watch, according to JF Apex Research.
5249 9385 7052 5236 5355
KUALA LUMPUR (Aug 27): Integrated livestock farming company Lay Hong Bhd’s first quarter net profit dropped 48% to RM2.28 million, from RM4.42 million a year ago, due to higher feed cost arising from rising exchange rate.
KUALA LUMPUR: The director-general of the Department of Veterinary Services Malaysia (DVS) Datuk Dr Quaza Nizamuddin Hassan Nizam will travel to Indonesia to explain to his counterpart there about the recent bird flu outbreak in Tuaran, Sabah, after Indonesia, banned the import of poultry from Malaysia.
KUALA LUMPUR (Aug 7): AllianceDBS Research said Lay Hong Bhd (Layhong) had on Aug 6 broken below the 71 sen support to reach an intraday low of 70.5 sen before closing off the day’s low at 71.5 sen (down 1 sen or 1.37%).
KUALA LUMPUR (Aug 3): Based on corporate announcements and news flow today, stocks in focus on Monday (Aug 6) may include: Gamuda Bhd, Kumpulan Perangsang Selangor Bhd, Bumi Armada Bhd, SLP Resources Bhd, Frontken Corp Bhd, Axiata Bhd, Anzo Holdings Bhd, Lay Hong Bhd, Amanah Harta Tanah PNB, Parlo Bhd, Nylex (Malaysia) Bhd, Ancom Bhd, YTL Power International Bhd, UEM Sunrise Bhd and T7 Global Bhd.
9385 BRDBF U96 HYFXY 7248 6742 9342 SCRPY 5210 5843 4952 5148 YTLPF HYFXF SCRPF
2018-08-03 theedgemarkets - 2
KUALA LUMPUR (Aug 3): Poultry and eggs firm Lay Hong Bhd is allocating RM13 million or about 50% of the proceeds from the disposal of its land in Ijok, Selangor, to build a broiler grand parent stock farm in Raub, Pahang next year.
2018-08-02 thestar.com.my - 2
In a filing with Bursa Malaysia, LHB said it would provide JKSB with limited power of attorney for building plan submission and other land matters before the completion of sale and purchase agreement between both parties
9385 BSMAF 1818
KUALA LUMPUR (Aug 1): Lay Hong Bhd plans to dispose of its 34-acre land in Ijok, Kuala Selangor, to Kejora Sdn Bhd (JKSB) for RM27.60 million, to raise funds to pare down its borrowings.
9385 BSMAF 1818
2018-07-27 theedgemarkets - 1
KUALA LUMPUR (July 27): Lay Hong Bhd was actively traded today after its executive chairman Yap Hoong Chai disposed of his 598,000 warrants in the company.
9385 BSMAF 1818
KUALA LUMPUR (July 27): The FBM KLCI was down marginally at mid-morning, tracking losses at regional markets.
9385 GMALF 4065 7113 TPGVF BATS 4162 5202 7123 CIMDF GMALY TGLVY KLKBY 1023 2445 5347 2542 4715 TNABY 4723 2739 TNABF 3719
KUALA LUMPUR (July 26): The FBM KLCI finished 2.45 points or 0.14% higher, helped by the 11th-hour share price spike in index-linked stocks like Tenaga Nasional Bhd and Malayan Banking Bhd (Maybank).
1155 9385 5347 MLYBY TNABY MLYNF TNABF 3719
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...